文献速递妇科

术后并发症对晚期上皮性卵巢癌初次或间歇性肿瘤细胞减灭术中行肠道手术患者结局的影响:纪念斯隆凯特琳癌症中心Team Ovary研究

Impact of postoperative morbidity on outcomes in patients with advanced epithelial ovarian cancer undergoing intestinal surgery at the time of primary or interval cytoreductive surgery: A Memorial Sloan Kettering Cancer Center Team Ovary study.
PubMed 文献 · Gynecol Oncol · 2023-11-21

该回顾性队列纳入2015年1月1日至2020年12月31日在本机构因卵巢癌行初次肿瘤细胞减灭术(PCS)或间歇性肿瘤细胞减灭术(ICS)且至少行一处肠切除的437例患者,分析术后30天内短期并发症(外科次要事件SSE)对无进展生存(PFS)和总生存(OS)的影响,结果显示PCS和ICS队列中发生SSE与未发生SSE者的PFS和OS均无显著差异。

要点

  • 437例中PCS 289例、ICS 148例,183例(42%)行1处肠切除,180例(41%)行2处,74例(17%)行3处。
  • 术后吻合口漏6例(1.4%),无围手术期死亡。
  • PCS队列发生SSE与未发生SSE者PFS的HR为1.05(95%CI 0.76-1.47,p=0.75),OS的HR为0.79(95%CI 0.49-1.26,p=0.32)。

核心结论

  • 晚期卵巢癌初次手术管理中行肠道手术的患者,短期术后并发症未影响肿瘤学结局。

研究设计与样本

  • 回顾性病历审查,纳入2015年1月1日至2020年12月31日在本机构行PCS或ICS且至少行一处肠切除的卵巢癌患者437例,PCS 289例、ICS 148例,分别分析PFS和OS。

主要发现

  • 437例中183例(42%)行1处肠切除,180例(41%)行2处,74例(17%)行3处。
  • 术后吻合口漏6例(1.4%),无围手术期死亡。
  • PCS队列发生SSE与未发生SSE者PFS的HR为1.05(95%CI 0.76-1.47,p=0.75),OS的HR为0.79(95%CI 0.49-1.26,p=0.32)。
  • ICS队列发生SSE与未发生SSE者PFS的HR为1.43(95%CI 0.99-2.07,p=0.055),OS的HR为1.18(95%CI 0.72-1.93,p=0.52)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the impact of short-term postoperative complications on oncologic outcomes for patients with epithelial ovarian cancer undergoing primary cytoreductive surgery (PCS) or interval cytoreductive surgery (ICS) with intestinal resection. METHODS: A retrospective chart review was performed for patients with ovarian cancer who underwent PCS or ICS with at least one intestinal resection at our institution from 1/1/2015 to 12/31/2020. Progression-free survival (PFS) and overall survival (OS) were analyzed for the PCS and ICS cohorts separately. Short-term complications within 30 days of surgery (surgical secondary events [SSEs]) were graded by a validated institutional SSE system. RESULTS: Among 437 patients who underwent intestinal resections during PCS (n = 289) or ICS (n = 148), 183 (42%) had one, 180 (41%) had two, and 74 (17%) had three intestinal resections. Six (1.4%) of 437 patients experienced an anastomotic leak postoperatively. There were no perioperative deaths. There was no difference in PFS and OS for patients who underwent PCS with any SSE vs. no SSE within 30 days of surgery (HR, 1.05; 95% CI: 0.76-1.47; p = 0.75 and HR, 0.79; 95% CI: 0.49-1.26; p = 0.32, respectively). There was no difference in PFS and OS for patients who underwent ICS with any SSE vs. no SSE within 30 days of surgery (HR, 1.43; 95% CI: 0.99-2.07; p = 0.055 and HR. 1.18; 95% CI: 0.72-1.93; p = 0.52, respectively. CONCLUSION: Short-term postoperative morbidity for patients who underwent intestinal surgery during primary surgical management for advanced ovarian cancer did not impact oncologic outcomes.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Praiss AM, Hirani R, Zhou Q, et al. Impact of postoperative morbidity on outcomes in patients with advanced epithelial ovarian cancer undergoing intestinal surgery at the time of primary or interval cytoreductive surgery: A Memorial Sloan Kettering Cancer Center Team Ovary study. Gynecol Oncol. 2023. PMID: 37992548. doi:10.1016/j.ygyno.2023.10.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。